Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Towards the end of 2021, SARS-CoV-2 vaccine effectiveness was threatened by the emergence of the omicron clade (B.1.1.529), with more than 30 mutations in the spike protein. Recently, several sublineages of omicron, including BA.2.12.1, BA.4, and BA.5, have shown even greater immune evasion, and are driving waves of infections worldwide.

One emerging sublineage, BA.2.75, is increasing in frequency in India and had been detected in at least 15 countries as of July 19, 2022. Relative to BA.2, BA.2.75 carries nine additional mutations in the spike protein (appendix p 2): K147E, W152R, F157L, I210V, G257S, G339H, G446S, N460K, and a reversion towards the ancestral variant, R493Q. G446S has been predicted to be a site of potential escape from antibodies elicited by current vaccines that still neutralise ancestral B.1 (D614G), in line with its potency against BA.5 (figure A; appendix pp 4–5). Although only capable of extremely weak neutralisation of BA.2, tixagevimab showed partially restored activity against BA.2.75, possibly due, in part, to the reversion to the ancestral amino acid at spike position 493. Although bebtelovimab showed reduced potency against BA.2.75, probably due to G446S, the reduction was only around 7-fold, and bebtelovimab still potently neutralised BA.2.75. Casirivimab, imdevimab, bamlanivimab, and etesevimab did not neutralise BA.2.75. The relative sensitivity of BA.2.75 observed here is largely concordant with data from two other studies, although the magnitude of the loss of potency for cilgavimab shows substantial variation between the three studies.

BA.2.75 was neutralised with the lowest geometric mean ID\(_{50}\) titre of all variants evaluated by serum sampled before the BA.1 and BA.2 infection wave (Nov 8–14, 2022; figure B), with titres to BA.2.75 approximately 8-times lower compared with ancestral B.1 (D614G). For sera sampled before the infection wave, titres against BA.2.75 were slightly but significantly lower than those against BA.2, and similar to those against BA.5. Sera sampled following the BA.1 and BA.2 infection wave showed substantially increased neutralisation against ancestral B.1, as well as enhanced cross-neutralisation of omicron sublineage BA.2.75.

### Figure: Evasion of neutralising antibodies by BA.2.75

(A) Neutralising 50\% inhibitory concentration (IC\(_{50}\)) titres (ng/μl) for monoclonal antibodies against ancestral B.1 (D614G) and omicron sublineages BA.2, BA.5, and BA.2.75 in a pseudovirus neutralisation assay. (B) Neutralisation of BA.2.75 relative to BA.2, BA.5, and B.1 by serum (n=20) from blood donated Nov 8–14, 2021, in Stockholm, Sweden, before a wave of infections dominated by BA.1 and BA.2 (left-hand chart). Neutralisation by serum (n=20) donated April 11–17, 2022, after the infection wave (right-hand chart). Values shown above the charts in (B) are the geometric mean ID\(_{50}\) titres. Serum with an ID\(_{50}\) less than the lowest dilution tested (20, dotted line) is plotted as 20. ID\(_{50}\)=50\% inhibitory dilution.
sublineages. Geometric mean titres against BA.2.75 after the BA.1 and BA.2 infection wave were more than 7 times those of sera sampled before the wave of infections (appendix p 6), probably reflecting a combined contribution of BA.1 and BA.2 infections, as well as third-dose booster vaccine rollout, with coverage in Stockholm expanding among people aged 18 years or older from 5% during Nov 8–14, 2021, to 59% during April 11–17, 2022 (appendix p 3). During April 11–17, 2022, titres against BA.2.75 were slightly but significantly lower than those against BA.2, and similar to those against BA.5. The relative sensitivity of BA.2.75 in these cohorts of blood donors is largely concordant with those seen in vaccinated individuals (CoronaVac; Sinovac Life Sciences, Beijing, China) with and without BA.1 or BA.2 breakthrough infection.7

As infection histories become more complex, and a large proportion of infections go undetected, monitoring of population-level immunity from random samples is increasingly crucial for understanding and contextualising the immune evasion properties of new SARS-CoV-2 variants. Here we show that the emerging sublineage, BA.2.75, does not show greater antibody evasion than the currently dominating BA.5 variant in a set of random samples from Stockholm. BA.2.75 largely maintains sensitivity to bebtelovimab despite a slight reduction in potency, and exhibits moderate susceptibility to tixagevimab and cilgavimab.

STR is a cofounder of, and held shares in, deepCDR Biologics, which has been acquired by AlloY Therapeutics. DJS, GBKH, and BM have intellectual property rights associated with antibodies that neutralise omicron variants. All other authors declare no competing interests.

Daniel J Sheward, Changji Kim, Julian Fischbach, Sandra Muschiol, Roy A Ehling, Niklas K Björkström, Gunilla B Karlsson Hedestam, Sai T Reddy, Jan Albert, Thomas P Peacock, *Ben Murrell
benjamin.murrell@ki.se

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 65, Sweden (DJS, CK, JP, SM, GBKH, JA, BM), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (DJS), Department of Biosystems Science and Engineering, ETH Zurich, Zurich, Switzerland (RAE, STR), Center for Infectious Medicine, Department of Medicine-Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden (NKB), Department of Infectious Disease, Imperial College London, London, UK (TPP)

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage

After its first identification in a sample collected at the end of May, 2022, genome surveillance revealed a rapid increase of the omicron BA.2.75 sublineage to more than 30% of sequenced SARS-CoV-2 infections in India by mid-July, 2022.1 Moreover, cases of BA.2.75 infections have been reported in numerous countries globally.7 Accordingly, on July 15, 2022, the European Centre for Disease Prevention and Control elevated the BA.2.75 sublineage to a variant of interest. Compared with the parental BA.2 lineage of SARS-CoV-2, the spike protein of BA.2.75 differs in nine amino acid residues in the N-terminal domain (K147E, W152F, F157L, I210V, and G257S) and the receptor binding domain (D339H, G446S, N460K, and R493Q; appendix p 2). By affecting crucial epitopes, mutations in these domains can confer a growth advantage through reduced susceptibility to SARS-CoV-2 neutralising antibodies.2 To investigate antibody sensitivity of BA.2.75 in comparison with prevalent omicron sublineages, we performed neutralisation assays using pseudoviruses expressing the B.1 (D614G), BA.2, BA.4/5, BA.2.12.1, or BA.2.75 spike proteins.

First, we determined 50% inhibitory dilutions (ID50) in serum samples collected 4 weeks after administration of a BNT162b2 vaccine booster dose in a cohort of 30 health-care workers and older individuals (aged >70 years; appendix pp 5–6). All individuals had received three BNT162b2 doses, and no intermittent SARS-CoV-2 infections were reported. Although the neutralising activity against omicron sublineages was considerably lower than that against B.1, the differences between individual omicron sublineages were more subtle (figure A; appendix p 3). Serum activity against BA.2.75 was significantly lower than that against BA.2 (p=0.0145) but higher than the serum activity against BA.4/5 (p=0.0329; appendix p 3).

Next, we investigated the activity of 17 monoclonal antibodies conditionally authorised for use against COVID-19 or in advanced stages of clinical investigation by determining their 50% inhibitory concentrations (IC50). Most antibodies did not neutralise BA.2, BA.4/5, or BA.2.12.1 (IC50 >10 µg/mL). However, several of these antibodies showed appreciable activity against BA.2.75 (figure B; appendix p 4). For example, tixagevimab and regdanvimab, authorised for COVID-19 prevention.